Designing a randomized phase I/II prostate cancer chemoprevention trial using 1α-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D 3

S. Packianathan, Rajendra G. Mehta, Rajeshwari R. Mehta, William H. Hall, Philip S. Boerner, Laurel A Beckett, Srinivasan Vijayakumar

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Prostate cancer continues to be a significant source of morbidity and mortality among older men. One possible means of reducing its impact on overall health and vitality is via cancer chemoprevention, both in the population that is unaffected but at some risk and in those who have undergone some form of curative therapy after the onset of the disease. Chemoprevention holds significant promise, but large phase III clinical trials evaluating chemopreventive agents in prostate cancer can require vast numbers of enrollees and require the commitment of significant financial resources and time before any therapeutic benefit may become apparent. One technique to shorten the time required for chemoprevention clinical trials is to use surrogate endpoint biomarkers in place of the currently used actual endpoints of cancer incidence or survival. The validation of such surrogate endpoint biomarkers will require small, well-designed phase I and/or II trials to accumulate data on the modulation of the surrogate biomarkers and the endpoints of cancer incidence or survival by the chemopreventive agent. Careful statistical correlation and clinical validation of the data will then allow us to justify the use such surrogates in place of the actual endpoint in large, randomized trials, potentially shortening trial duration, improving financial efficiency, and accelerating approval of the chemopreventive agent. To that end, we first review the theoretical construct of cancer chemoprevention trials with particular reference to prostate cancer. We thereafter describe the design of a small, randomized, double-blinded, placebo-controlled phase I/II clinical trial of an analogue of vitamin D, vitamin D5, which we believe could serve as a model for data accumulation on surrogate biomarkers and correlation with other clinical endpoints.

Original languageEnglish (US)
Pages (from-to)357-367
Number of pages11
JournalCancer Journal
Volume10
Issue number6
StatePublished - Nov 2004

Fingerprint

Cholecalciferol
Chemoprevention
Prostatic Neoplasms
Biomarkers
Neoplasms
Phase III Clinical Trials
Phase II Clinical Trials
Clinical Trials, Phase I
Survival
Incidence
Controlled Clinical Trials
Tumor Biomarkers
Vitamin D
Vitamins
Placebos
Clinical Trials
Morbidity
Mortality
Health
Therapeutics

Keywords

  • Chemoprevention
  • Phase I/II
  • Prostate cancer
  • Radiation therapy
  • Randomized clinical trial
  • Vitamin D

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Packianathan, S., Mehta, R. G., Mehta, R. R., Hall, W. H., Boerner, P. S., Beckett, L. A., & Vijayakumar, S. (2004). Designing a randomized phase I/II prostate cancer chemoprevention trial using 1α-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D 3 Cancer Journal, 10(6), 357-367.

Designing a randomized phase I/II prostate cancer chemoprevention trial using 1α-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D 3 . / Packianathan, S.; Mehta, Rajendra G.; Mehta, Rajeshwari R.; Hall, William H.; Boerner, Philip S.; Beckett, Laurel A; Vijayakumar, Srinivasan.

In: Cancer Journal, Vol. 10, No. 6, 11.2004, p. 357-367.

Research output: Contribution to journalArticle

Packianathan, S, Mehta, RG, Mehta, RR, Hall, WH, Boerner, PS, Beckett, LA & Vijayakumar, S 2004, 'Designing a randomized phase I/II prostate cancer chemoprevention trial using 1α-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D 3 ', Cancer Journal, vol. 10, no. 6, pp. 357-367.
Packianathan, S. ; Mehta, Rajendra G. ; Mehta, Rajeshwari R. ; Hall, William H. ; Boerner, Philip S. ; Beckett, Laurel A ; Vijayakumar, Srinivasan. / Designing a randomized phase I/II prostate cancer chemoprevention trial using 1α-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D 3 In: Cancer Journal. 2004 ; Vol. 10, No. 6. pp. 357-367.
@article{98dfb74f199a4ef99b12dbece85e89cb,
title = "Designing a randomized phase I/II prostate cancer chemoprevention trial using 1α-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D 3",
abstract = "Prostate cancer continues to be a significant source of morbidity and mortality among older men. One possible means of reducing its impact on overall health and vitality is via cancer chemoprevention, both in the population that is unaffected but at some risk and in those who have undergone some form of curative therapy after the onset of the disease. Chemoprevention holds significant promise, but large phase III clinical trials evaluating chemopreventive agents in prostate cancer can require vast numbers of enrollees and require the commitment of significant financial resources and time before any therapeutic benefit may become apparent. One technique to shorten the time required for chemoprevention clinical trials is to use surrogate endpoint biomarkers in place of the currently used actual endpoints of cancer incidence or survival. The validation of such surrogate endpoint biomarkers will require small, well-designed phase I and/or II trials to accumulate data on the modulation of the surrogate biomarkers and the endpoints of cancer incidence or survival by the chemopreventive agent. Careful statistical correlation and clinical validation of the data will then allow us to justify the use such surrogates in place of the actual endpoint in large, randomized trials, potentially shortening trial duration, improving financial efficiency, and accelerating approval of the chemopreventive agent. To that end, we first review the theoretical construct of cancer chemoprevention trials with particular reference to prostate cancer. We thereafter describe the design of a small, randomized, double-blinded, placebo-controlled phase I/II clinical trial of an analogue of vitamin D, vitamin D5, which we believe could serve as a model for data accumulation on surrogate biomarkers and correlation with other clinical endpoints.",
keywords = "Chemoprevention, Phase I/II, Prostate cancer, Radiation therapy, Randomized clinical trial, Vitamin D",
author = "S. Packianathan and Mehta, {Rajendra G.} and Mehta, {Rajeshwari R.} and Hall, {William H.} and Boerner, {Philip S.} and Beckett, {Laurel A} and Srinivasan Vijayakumar",
year = "2004",
month = "11",
language = "English (US)",
volume = "10",
pages = "357--367",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "1528-9117",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Designing a randomized phase I/II prostate cancer chemoprevention trial using 1α-hydroxy-24-ethyl-cholecalciferol, an analogue of vitamin D 3

AU - Packianathan, S.

AU - Mehta, Rajendra G.

AU - Mehta, Rajeshwari R.

AU - Hall, William H.

AU - Boerner, Philip S.

AU - Beckett, Laurel A

AU - Vijayakumar, Srinivasan

PY - 2004/11

Y1 - 2004/11

N2 - Prostate cancer continues to be a significant source of morbidity and mortality among older men. One possible means of reducing its impact on overall health and vitality is via cancer chemoprevention, both in the population that is unaffected but at some risk and in those who have undergone some form of curative therapy after the onset of the disease. Chemoprevention holds significant promise, but large phase III clinical trials evaluating chemopreventive agents in prostate cancer can require vast numbers of enrollees and require the commitment of significant financial resources and time before any therapeutic benefit may become apparent. One technique to shorten the time required for chemoprevention clinical trials is to use surrogate endpoint biomarkers in place of the currently used actual endpoints of cancer incidence or survival. The validation of such surrogate endpoint biomarkers will require small, well-designed phase I and/or II trials to accumulate data on the modulation of the surrogate biomarkers and the endpoints of cancer incidence or survival by the chemopreventive agent. Careful statistical correlation and clinical validation of the data will then allow us to justify the use such surrogates in place of the actual endpoint in large, randomized trials, potentially shortening trial duration, improving financial efficiency, and accelerating approval of the chemopreventive agent. To that end, we first review the theoretical construct of cancer chemoprevention trials with particular reference to prostate cancer. We thereafter describe the design of a small, randomized, double-blinded, placebo-controlled phase I/II clinical trial of an analogue of vitamin D, vitamin D5, which we believe could serve as a model for data accumulation on surrogate biomarkers and correlation with other clinical endpoints.

AB - Prostate cancer continues to be a significant source of morbidity and mortality among older men. One possible means of reducing its impact on overall health and vitality is via cancer chemoprevention, both in the population that is unaffected but at some risk and in those who have undergone some form of curative therapy after the onset of the disease. Chemoprevention holds significant promise, but large phase III clinical trials evaluating chemopreventive agents in prostate cancer can require vast numbers of enrollees and require the commitment of significant financial resources and time before any therapeutic benefit may become apparent. One technique to shorten the time required for chemoprevention clinical trials is to use surrogate endpoint biomarkers in place of the currently used actual endpoints of cancer incidence or survival. The validation of such surrogate endpoint biomarkers will require small, well-designed phase I and/or II trials to accumulate data on the modulation of the surrogate biomarkers and the endpoints of cancer incidence or survival by the chemopreventive agent. Careful statistical correlation and clinical validation of the data will then allow us to justify the use such surrogates in place of the actual endpoint in large, randomized trials, potentially shortening trial duration, improving financial efficiency, and accelerating approval of the chemopreventive agent. To that end, we first review the theoretical construct of cancer chemoprevention trials with particular reference to prostate cancer. We thereafter describe the design of a small, randomized, double-blinded, placebo-controlled phase I/II clinical trial of an analogue of vitamin D, vitamin D5, which we believe could serve as a model for data accumulation on surrogate biomarkers and correlation with other clinical endpoints.

KW - Chemoprevention

KW - Phase I/II

KW - Prostate cancer

KW - Radiation therapy

KW - Randomized clinical trial

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=15744398245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15744398245&partnerID=8YFLogxK

M3 - Article

C2 - 15701267

AN - SCOPUS:15744398245

VL - 10

SP - 357

EP - 367

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 1528-9117

IS - 6

ER -